Caryn Fenner and Petro Terblanche outline Afrigen's clinical trial plans, local partnerships, and vaccine pipeline.
The ongoing H5N1 avian flu outbreak has severely impacted U.S. poultry and dairy industries, prompting a $1 billion USDA response strategy that includes biosecurity, vaccination research, and innovation funding. With growing concern over viral mutations affecting humans and livestock, rapid, field-based diagnostic tools offer critical support in accelerating detection and containment efforts.
After the leaders of the NIH, FDA, and HHS made an announcement stating that both pregnant women and children were going to be taken off the COVID-19 immunization schedule, they decided to offer a new designation for the latter group, making it a shared decision between providers and patients.
Outpatient parenteral antimicrobial therapy (OPAT) offers benefits for patients as well as providing cost effectiveness; however, it is not without its challenges. Two clinicians provide insights on this modality.
New data at CROI 2025 shows zero cases of HIV acquisition reported with Apretude (cabotegravir long-acting (CAB LA) for PrEP in varied clinical settings and populations in 2 implementation studies in the US and Brazil.
In the latest column from SIDP, handshake stewardship prioritizes face-to-face communication between frontline providers to enable feedback to assess the appropriateness of prescribed antimicrobials.
Evelyn Wu, MD, reveals a rise in tick-borne diseases in New Jersey over the past two decades and correlations with the influence of warming climate conditions.
In the latest SIDP column, two clinicians provide information on recent studies and guidelines directed at antibiotic durations in this patient population.
There have been sporadic cases Hemophagocytic Lymphohistiocytosis, associated with Cytomegalovirus Infection infection, suggesting that CMV may cause clinically significant disease beyond mononucleosis in immunocompetent individuals.
A food for thought as an ambulatory antibiotic stewardship initiative.
John McLaughlin, PhD, examines high-risk individuals with prior SARS-CoV-2 immunity and presents that Paxlovid reduces the risk of hospitalization, death, and severe symptoms, highlighting its ongoing value for high-risk patients in a post-peak pandemic landscape.
At MAD-ID, Dianne Nguyen, MD, shares Phase 3 data showing consistent tolerability of the microbiome therapy across high-risk patient populations
Here is a case study involving a patient with the virus and the clinical approach in thinking about appropriate treatment while keeping stewardship in mind.
Internal tremors are a newly recognized and troubling symptom of Long COVID, experienced by over one-third of participants in a Yale-based study
Here is a look at some of the treatment alternatives, which can offer simpler logistics and cost considerations.
In the latest column from the Society of Infectious Diseases Pharmacists (SIDP), here is a discussion on the use of rifampin as an adjunctive antibiotic treatment for patients with diabetic foot osteomyelitis.
David Richards emphasized the therapy’s potential to enhance antibiotic effectiveness by targeting bacterial biofilms, a significant challenge in treatment.
Changes in microbiology and antimicrobial resistance patterns warrant reevaluation of our current therapies for this condition.
The Peggy Lillis Foundation's (PLF) CEO and Cofounder Christian John Lillis talks about these important events happening in the capital at the end of this month.
Alexander Laurenson presents T-cell-focused tool at the 2025 Vaccinology Conference using data from 18 countries and 748 HLA alleles to address immune diversity in Africa.
Larry Sutton, MD, PhD, discussed how oxygen affects C. difficile and provides anti-inflammatory effects in the gut, with potential applications for gastrointestinal diseases.
The OASIS platform will help outpatient facilities use prescribing data to improve patient care.
A decreasing number of researchers and open positions for infectious disease clinicians and limited residency matches are underlying issues that should be addressed to meet the needs around antimicrobial development and clinical care. Amesh Adalja, MD, FIDSA, discusses some of the challenges behind it.
Timothy Ritter, MD, provides his insights on using the live biotherapeutic product and what both patients and clinicians can expect in terms of safety and efficacy.
A panel discusses how vaccine policy under new federal government policies, why misinformation has flourished and what individual providers can do to win back patient trust.
Gilead Sciences has partnered with the Global Fund to supply up to 2 million doses of its long-acting HIV prevention drug, lenacapavir, to low and lower-middle income countries.